[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ckd-chronic-kidney-disease-stage-5d\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ckd-chronic-kidney-disease-stage-5d":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,78,110,137,162,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100586305","phase-2-effect-of-canagliflozin-on-ultrafiltration--fibrosis-in-patients-on-peritoneal-dialysis-100586305",false,"NCT06913647","Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","Effect of Canagliflozin on Ultrafiltration and Fibrosis in Peritoneal Dialysis: a a Proof-of-concept Randomized Phase II Crossover Clinical Trial","CAN-PD","Inclusion Criteria:\n\n* Adult patients with kidney failure on PD (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months.\n* Only high or high-average transporters, as classified by PET, will be included.\n\nExclusion Criteria:\n\n* History of euglycemic ketoacidosis\n* Known hypersensitivity to canagliflozin\n* Active peritonitis or tunnel infection\n* Kidney transplant scheduled in the next 6 months\n* Severe liver cirrhosis (Child-Pugh class C stage)\n* Recurrent severe genital or urine infections\n* Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.\n\nThe primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.",[27,28],"ESRD","CKD (Chronic Kidney Disease) Stage 5D",[30,31,32,33,34],"SGLT-2 inhibitors","Canagliflozin","Ultrafiltration failure","Peritoneal fibrosis","Peritoneal dialysis","RECRUITING","2026-03-12",{"date":38,"type":39},"2026-03-16","ACTUAL",{"date":41,"type":39},"2026-02-01",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100621938","tubeless-spontaneous-ventilation-anesthesia-in-kidney-transplantation-100621938","NCT07377123","Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation","Application of Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation Surgery: A Single-Center, Prospective, Randomized Controlled Trails","Inclusion Criteria:\n\n1. No gender restriction, age 18-65 years (including upper and lower limits).\n2. First-time recipient of citizen organ donation kidney transplantation.\n3. Type of citizen organ donation must be Category I China (Donation after Brain Death DBD).\n4. Donor and recipient blood type identical.\n5. Panel reactive antibody (PRA) results negative within six months preoperatively.\n6. Body mass index (BMI) \\\u003C28 kg\u002Fm².\n7. No severe pulmonary ventilation or gas exchange dysfunction, preoperative pulmonary function assessment meets kidney transplantation requirements, preoperative chest CT shows no significant abnormalities.\n8. No severe arrhythmia (frequent atrial fibrillation or ventricular premature beats), normal cardiac function (ejection fraction \\> 50%).\n9. American Society of Anesthesiologists (ASA) physical status classification ≤ III.\n10. Voluntarily participate in clinical research, fully understand this study and voluntarily sign the informed consent form, and complete all trial procedures.\n\nExclusion Criteria:\n\n1. Combined multi-organ transplantation.\n2. Previous history of organ transplantation other than kidney.\n3. Living donor kidney transplantation.\n4. If one of the two patients receiving a kidney from the same donor does not meet the inclusion criteria, the other patient is also excluded.\n5. Previous history of mental illness, current psychological assessment does not meet transplantation criteria.\n6. Other situations where the organ transplant physician assesses the patient as not suitable for transplantation.\n7. Poor compliance of the recipient or other situations deemed by the researcher as unsuitable for inclusion in the trial.","65 Years",{"count":57,"type":21},60,[59],"NA","The aim of this clinical trial is to compare the intraoperative use of neuromuscular blocking agents and other anesthetic drugs between tubeless spontaneous ventilation anesthesia (TSVA) and conventional endotracheal intubation (ETT) anesthesia in kidney transplantation. The study will also evaluate the safety, stability, and postoperative recovery associated with TSVA.\n\nThis trial is designed to address the following questions:\n\n* Does TSVA reduce the intraoperative requirement for neuromuscular blocking agents and other anesthetic medications?\n* Does TSVA improve postoperative outcomes in kidney transplant recipients?\n* How do the intraoperative safety and stability of TSVA compare with those of ETT anesthesia?\n\nResearchers will compare anesthetic drug consumption, intraoperative anesthetic performance, and postoperative recovery outcomes between the TSVA and ETT groups to determine whether TSVA can decrease anesthetic drug use and enhance patient recovery.\n\nParticipants will:\n\n* Undergo a complete preoperative assessment\n* Receive kidney transplantation under TSVA or ETT anesthesia, with relevant intraoperative data recorded\n* Receive tubeless postoperative management, with documentation of pain scores, complications, and recovery of graft function\n* Be followed throughout their lifetime after discharge, providing long-term follow-up information",[62,28],"Kidney Transplantation",[64,65,66,67],"kidney transplantation","tubeless","ERAS","anesthesia","NOT_YET_RECRUITING","2026-01-22",{"date":71,"type":39},"2026-01-29",{"date":73,"type":21},"2026-01-12",{"date":75,"type":21},"2027-12-31",{"name":77,"class":46},"Jianxing He",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":47},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469","NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy",{"count":57,"type":21},[59],"Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[28,90,91,92,93,94,95,96],"Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[98,99,100],"Program dialysis","Sorption","Complications of program dialysis","2025-12-03",{"date":103,"type":39},"2025-12-10",{"date":105,"type":39},"2025-06-01",{"date":107,"type":21},"2026-06-30",{"name":109,"class":46},"Botkin Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100391757","phase-4-aspirin-in-reducing-events-in-dialysis--aspired--100391757","NCT04381143","ASPIrin in Reducing Events in Dialysis ( ASPIRED )","ASPIrin in Reducing Events in Dialysis","Inclusion Criteria:\n\n* Incident or prevalent adults (≥18 years old) dialysis patients are included in the Dialysis Registry.\n* Commenced on dialysis with the expectation of ongoing maintenance dialysis requirement.\n* Willing and able to provide informed consent for this study.\n\nExclusion Criteria:\n\n* Requirement for any form of antiplatelet agent (aspirin, glycoprotein IIb\u002FIIIa inhibitors etc), or oral anticoagulation (warfarin, NOACs), in the view of the treating physician.\n* Contraindication to aspirin, in the view of the treating physician.\n* Dialysis requirement due to acute kidney injure with expectation of kidney function recovery.\n* History of haemorrhagic stroke or intracranial bleed within 12 months of screening.\n* Coagulopathy from any cause.\n* Unable to provide informed consent.",{"count":118,"type":21},9000,[120],"PHASE4","People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.",[28],[124,125,126],"Aspirin","Dialysis","End Stage Kidney Disease","2025-11-14",{"date":129,"type":39},"2025-11-18",{"date":131,"type":39},"2020-07-30",{"date":133,"type":21},"2026-12",{"name":135,"class":46},"Guangdong Provincial People's Hospital",139,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":47},"100567695","effect-of-kidney-replacement-therapy-with-polymethylmethacrylate-membranes-on-pruritus-related-quality-of-life-in-patients-receiving-maintenance-haemodialysis-100567695","NCT06671535","Effect of Kidney Replacement Therapy with Polymethylmethacrylate Membranes on Pruritus-related Quality of Life in Patients Receiving Maintenance Haemodialysis","Inclusion Criteria:\n\n* Diagnosis of CKD stage 5D, maintenance hemodialysis not less than 3 months prior screening;\n* Moderate-to-severe pruritis (WI-NRS score ≥ 4);\n* Adequate dialysis dose (spKt\u002FV≥1,4 and\u002For eKt\u002FV≥1,2);\n* Dialysis treatment regimen: three sessions per week of at least 4 hours duration;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of active skin disease, cholestasis, severe secondary hyperparathyroidism and other conditions that, in the investigator's opinion, may be responsible for pruritus.\n* Noncompliance of the patient with the protocol (in the investigator's opinion).\n* Use of haemodiafiltration.",{"count":144,"type":21},62,[59],"This randomized controlled trial aims to evaluate the effect of polymethylmethacrylate dialysis membranes use on the intensity of pruritus in patients with CKD stage 5D receiving maintenance hemodialysis.\n\nThe main question it aims to answer is: Does the use of polymethylmethacrylate (PMMA) membranes reduce the intensity of pruritus in dialysis patients?\n\nResearchers will compare PMMA membranes to standard polysulfone-based membranes to see if PMMA works to reduce moderate-to-severe pruritis and pruritis-related quality of life.\n\nParticipants will:\n\n* receive maintenance hemodialysis with PMMA or polysulfone membranes for 2 months;\n* fill in questionnaires about intensity of pruritis and its impact on daily life.",[28,93,148],"Pruritis",[150,151,152],"polymethylmethacrylate membranes","CKD-associated pruritis","PMMA membranes","2025-03-02",{"date":155,"type":39},"2025-03-04",{"date":157,"type":39},"2025-01-27",{"date":159,"type":21},"2025-10",{"name":161,"class":46},"Saint Petersburg State University, Russia",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":47},"100505214","impact-of-propionic-acid-on-regulatory-t-cell-function-in-children-with-ckd-100505214","NCT05858437","Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD","Impact of Propionic Acid on Regulatory T Cell Function in Children With Chronic Kidney Disease","Pro-Kids","Inclusion Criteria:\n\n* Body weight: \\> 30kg\n* CKD G5 treated with hemodialysis\n* Continuous hemodialysis treatment for \\> 3 months\n* Clinical stable condition\n* Manifestation of CKD within childhood (\\\u003C18 years)\n\nExclusion Criteria:\n\n* Disease or dysfunctions, which disqualifies the patient\n* Incapacity of contract or any other circumstances, which prohibit the patient or his legal guardians from understanding setup, meaning and entity of the study\n* Acute infections\n* Immunosuppressive therapy within the last 12 weeks before the start of the study\n* Pre-\u002Fpro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study\n* Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study\n* Malignant diseases\n* Pregnancy\n* chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease\n* alcohol- or drug abuse\n* parallel participation on other interventional trials","12 Years","20 Years",{"count":173,"type":21},16,[59],"Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.",[28],"2025-02-14",{"date":179,"type":39},"2025-02-18",{"date":181,"type":39},"2024-01-15",{"date":183,"type":21},"2026-04",{"name":185,"class":46},"Charite University, Berlin, Germany",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":205,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100548112","genetics-in-the-progression-of-nephropathies-100548112","NCT06416761","Genetics in the Progression of Nephropathies","The Genetic Contribution to Progression of Kidney Disease","Inclusion Criteria:\n\n. presence of specific renal disease\n\nExclusion Criteria:\n\n* to be evaluated in the different sub-protocols",{"count":194,"type":21},10000,"OBSERVATIONAL","This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to:\n\n* AKI\n* CKD\n* Hypertension\n* ADPKD\n* CKD-MBD\n* Patients with decompensated heart failure undergoing either medical or surgery therapy\n* Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation\n* glomerular diseases",[198,199,200,28,201,202,203,204],"AKI","CKD","Ckd-Mbd","ADPKD","Hypertension","Hematologic Malignancy","Bone Marrow Transplant Complications",[206,207,208,209,210,211],"genetic in hypertensive kidney disease","salt intake in BP control and CKD progression","genetic in CKD","endogenous Ouabain as marker of AKI","protein intake restriction in CKD progression","hypertension in allogenic bone marrow transplantation","2024-05-11",{"date":214,"type":39},"2024-05-16",{"date":216,"type":39},"2006-05-19",{"date":218,"type":21},"2041-05-19",{"name":220,"class":46},"Ospedale San Raffaele"]